Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 118.68% is 11% below its 5-year average of 133.30%, around the middle of its 5-year range (0.00%–193.19%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.63% below its 12-month average of 128.49%.
Reported quarterly debt to assets ratio; no daily interpolation. Q3 FY2026 (2026-06-30): 118.68%.
DEBT TO ASSETS RATIO
118.68%
DEBT TO ASSETS RATIO AVG TTM
128.49%
DEBT TO ASSETS RATIO AVG 3Y
132.78%
DEBT TO ASSETS RATIO AVG 5Y
133.30%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-7.63%
CURRENT VS 3Y AVG
-10.62%
CURRENT VS 5Y AVG
-10.97%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 657 covered companies
CURRENT VS SECTOR MEDIAN
+118583.32%
vs the sector median at left
Embecta Corp.
Market Cap
$355.17M
Debt to Assets Ratio
118.68%
TTM Avg
128.49%
3Y Avg
132.78%
5Y Avg
133.30%
Market Cap
$356.23M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$356.23M
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$356.89M
Debt to Assets Ratio
0.61%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$357.37M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$346.15M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$375.13M
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Embecta Corp. (EMBC) | $355.17M | 118.68% | 128.49% | 132.78% | 133.30% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $356.23M | 0.00% | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $356.23M | 0.38% | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $356.89M | 0.61% | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.37M | 0.19% | N/A | N/A | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $346.15M | 0.03% | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $361.15M | 0.71% | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $337.51M | 0.24% | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $375.13M | 0.25% | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $330.92M | 0.10% | N/A | N/A | N/A |
Debt/Assets
118.7%
Debt/Equity
N/A
Current Ratio
1.68
Interest Coverage
3.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 118.68% |
| 2026-03-31 | 131.91% |
| 2025-12-31 | 131.06% |
| 2025-09-30 | 131.11% |
| 2025-06-30 | 129.68% |
| 2025-03-31 | 138.50% |
| 2024-12-31 | 137.22% |
| 2024-09-30 | 125.14% |
| 2024-06-30 | 130.39% |
| 2024-03-31 | 138.02% |
| 2023-12-31 | 134.44% |
| 2023-09-30 | 134.92% |
| 2023-06-30 | 130.97% |
| 2023-03-31 | 135.63% |
| 2022-12-31 | 137.23% |
| 2022-09-30 | 151.31% |
| 2022-06-30 | 156.72% |
| 2022-03-31 | 193.19% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.52% |
